Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgent...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2021-01-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/20210109.pdf |
| _version_ | 1817977782755393536 |
|---|---|
| author | HE Xi, JIAO Xiaodong, ZANG Yuansheng |
| author_facet | HE Xi, JIAO Xiaodong, ZANG Yuansheng |
| author_sort | HE Xi, JIAO Xiaodong, ZANG Yuansheng |
| collection | DOAJ |
| description | The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgently needed to find effective emerging prognostic markers. In the past few years, tumor mutational burden (TMB) was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy. Recently, there are also corresponding exploratory studies on EGFR-mutant NSCLC. In this review, we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC. |
| first_indexed | 2024-04-13T22:21:05Z |
| format | Article |
| id | doaj.art-5e1d8042b1494e6f81569f7e84f003c0 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-04-13T22:21:05Z |
| publishDate | 2021-01-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-5e1d8042b1494e6f81569f7e84f003c02022-12-22T02:27:14ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392021-01-01311697510.19401/j.cnki.1007-3639.2021.01.009Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer HE Xi, JIAO Xiaodong, ZANG Yuansheng0Department of Medical Oncology, Changzheng Hospital, Naval Military Medical University, Shanghai 200433, ChinaThe application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgently needed to find effective emerging prognostic markers. In the past few years, tumor mutational burden (TMB) was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy. Recently, there are also corresponding exploratory studies on EGFR-mutant NSCLC. In this review, we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC.http://www.china-oncology.com/fileup/1007-3639/PDF/20210109.pdfnon-small cell lung cancer| tumor mutational burden|epidermal growth factor receptor|next-generation sequencing|comprehensive genomic profiling| prognosis |
| spellingShingle | HE Xi, JIAO Xiaodong, ZANG Yuansheng Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer Zhongguo aizheng zazhi non-small cell lung cancer| tumor mutational burden|epidermal growth factor receptor|next-generation sequencing|comprehensive genomic profiling| prognosis |
| title | Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer |
| title_full | Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer |
| title_fullStr | Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer |
| title_full_unstemmed | Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer |
| title_short | Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer |
| title_sort | clinical research progress of tumor mutational burden in egfr mutant advanced non small cell lung cancer nbsp |
| topic | non-small cell lung cancer| tumor mutational burden|epidermal growth factor receptor|next-generation sequencing|comprehensive genomic profiling| prognosis |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/20210109.pdf |
| work_keys_str_mv | AT hexijiaoxiaodongzangyuansheng clinicalresearchprogressoftumormutationalburdeninegfrmutantadvancednonsmallcelllungcancernbsp |